| Patent application number | Description | Published |
|---|
| 20080234198 | Selective Vpac2 Receptor Peptide Agonists - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 09-25-2008 |
| 20080318845 | Selective Vpac2 Receptor Peptide Agonists - The present invention relates to peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 12-25-2008 |
| 20090082276 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 03-26-2009 |
| 20090118167 | Selective Vpac2 Receptor Peptide Agonists - The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. | 05-07-2009 |
| 20100009916 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 01-14-2010 |
| 20100048460 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 02-25-2010 |
| 20110152181 | OXYNTOMODULIN PEPTIDE ANALOGUE - The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity. | 06-23-2011 |
| 20110152182 | OXYNTOMODULIN PEPTIDE ANALOGUE - The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity. | 06-23-2011 |
